
|Articles|January 22, 2004
Prostate cancer immunotherapy extends survival, study shows
Patients with Gleason scores =7 receiving an investigational form of immunotherapy for prostate cancer showed a significant survival advantage.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants priority review to sBLA for EV plus pembrolizumab in cisplatin-ineligible MIBC
2
Kim Nguyen Chi, MD, on 177Lu-PSMA-617 vs docetaxel in mCRPC
3
Adjuvant durvalumab plus tremelimumab after RCC resection improves DFS
4
News Network: Prostate Cancer and Bladder Cancer at ESMO 2025
5